Similar articles

• [Acute severe fibrosing hepatitis associated with ciprofibrate treatment].

  Dumortier J, Slim R, Chevallier M, Boillot O, Thaunat JL, Vaillant E, Vial T, Bellemin B, Paliard P, Scoazec JY. Dumortier J, et al. Gastroenterol Clin Biol. 1999 Dec;23(12):1399-400. Gastroenterol Clin Biol. 1999. PMID: 10642628 French. No abstract available.
• [Cytolytic hepatic damage caused by ciprofibrate].

  Perault MC, Fievre JL, Dejean C, Martin A, Vandel B. Perault MC, et al. Gastroenterol Clin Biol. 1992;16(6-7):609. Gastroenterol Clin Biol. 1992. PMID: 1526424 French. No abstract available.
• [Acute rhabdomyolysis during treatment with ciprofibrate].

  Delangre T, Vernier L, Moore N, Mihout B. Delangre T, et al. Presse Med. 1990 Nov 24;19(39):1811-2. Presse Med. 1990. PMID: 2148009 French. No abstract available.
• Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.

  Turpin G, Bruckert E. Turpin G, et al. Atherosclerosis. 1996 Jul;124 Suppl:S83-7. doi: 10.1016/0021-9150(96)05861-3. Atherosclerosis. 1996. PMID: 8831920 Review.
• Tolerability of fibric acids. Comparative data and biochemical bases.

  Sirtori CR, Calabresi L, Werba JP, Franceschini G. Sirtori CR, et al. Pharmacol Res. 1992 Oct-Nov;26(3):243-60. doi: 10.1016/1043-6618(92)90212-t. Pharmacol Res. 1992. PMID: 1437989 Review.